GENINCODE ORD 1P

- GBX (-)

- 15 min delayed data - London Stock Exchange

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	GENI
ISIN:	GB00BL97B504

GENINCODE ORD 1P overview

> News12/11/2024 - 13:05 ACCESSWIRE published a news.

CARDIO inCode Publication in International Journal of Cardiology Cardiovascular Risk and Prevention 12/11/2024 - 08:00• • ACCESSWIRE • Stocks • More GENINCODE ORD 1P news...

Individuals with a high polygenic risk are likely to derive the most benefit from lifestyle change and/or therapeutic intervention IRVINE, CA / ACCESSWIRE / December 11, 2024 / GENinCode U.S., the genetics company focused on the prevention of cardiovascular disease, announces the publication in the International Journal of Cardiology Cardiovascular Risk and Prevention of a clinical research study on the ‘ Interplay between Lifestyle Factors and Polygenic Risk for Incident Coronary Heart...

Thank you Chart

> News09/20/2024 - 13:05 ACCESSWIRE published a news.

DISCOVER FH Collaboration With Family Heart Foundation, UT Southwestern, and Partners 09/20/2024 - 09:00• • ACCESSWIRE • Stocks • More GENINCODE ORD 1P news...

LIPID inCode tests patients to identify familial hypercholesterolemia and prevent cardiovascular disease OXFORD, ENGLAND / ACCESSWIRE / September 20, 2024 / GENinCode Plc (AIM:GENI), the genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces its collaboration with The Family Heart Foundation®, UT Southwestern, and other partner members to use the LIPID inCode® monogenic and polygenic test in US Primary and Secondary Care settings for the diagnosis of...

Thank you Chart

> News05/01/2024 - 14:15 ACCESSWIRE published a news.

CARDIO inCode-Score (CIC-Score) Presentation at the European Society of Cardiology 05/01/2024 - 10:00• • ACCESSWIRE • Stocks • More GENINCODE ORD 1P news...

Preventive Cardiology Congress Athens 2024 OXFORD, ENGLAND / ACCESSWIRE / May 1, 2024 / GENinCode Plc, the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, gave details of a presentation by Kaiser Permanente at the European Society of Cardiology (ESC) Preventive Cardiology congress in Athens, Greece, on the ‘Joint consideration of low-density lipoprotein cholesterol ("LDL-C") and polygenic risk for incident coronary heart disease in a multi-ethnic...

Thank you Chart

> News04/05/2024 - 13:05 ACCESSWIRE published a news.

CARDIO inCode-Score Clinical Publication on Polygenic Risk of Coronary Heart Disease 04/05/2024 - 09:00• • ACCESSWIRE • Stocks • More GENINCODE ORD 1P news...

US Study Publication in the American Journal of Preventive Cardiology OXFORD, UK / ACCESSWIRE / April 5, 2024 / GENinCode Plc ( www.genincode.com ) the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces today the publication by the American Journal of Preventive Cardiology of a study on ‘ Polygenic Risk and Incident Heart Disease in a large multiethnic cohort' 1 . . The Kaiser Permanente Division of Research study investigated more than 63,000...

Thank you Chart

> News09/12/2023 - 15:05 ACCESSWIRE published a news.

CARDIO inCode Study Results Presented at ESC Annual Meeting 09/12/2023 - 11:00• • ACCESSWIRE • Stocks • More GENINCODE ORD 1P news...

Coronary Heart Disease (CHD) prevention nearly twice as effective when using CARDIO inCode as method to target treatment OXFORD, UK / ACCESSWIRE / September 12, 2023 / GENinCode Plc (AIM - GENI), the polygenics company focused on the prevention of cardiovascular disease, announced the presentation by Kaiser Permanente on the ' Utility of the CARDIO inCode-Score CHD polygenic risk score for incident coronary heart disease interplay with lifestyle in a multi-ethnic cohort of more than 60,000...

Thank you Chart

Load more content